However despite the extreme contraction of investor sentiment and macroeconomic uncertainty, select companies in the pharmaceutical, biotech and healthcare sectors showed distinct strength.
Woojung Bio Kukjeon Pharmaceutical and CG Medtech recorded gains of approximately 25%, 14% and 12% respectively defying the broader market downturn.
Woojung Bio stock trend on Mar 3.(Image=MP Doctor)
◇Woojung Bio 25% Surge on AI + Organ-on-a-Chip Innovation
Woojung Bio closed at 2,945 won, up approximately 25% from the previous session. The momentum continued in after hours trading maintaining a nearly 29% gain at 3,030 won. This surge is attributed to a strong influx of buying interest as news of recent global partnerships began to be fully priced in.
As a specialist in Contract Research Organizations (CRO), Woojung Bio operates leading laboratory animal, drug analysis and efficacy evaluation centers. To meet the growing global demand for alternatives to animal testing, the company is aggressively securing new growth engines:
Strategic Partnership with Xellar Biosystems: Woojung Bio teamed up with the Boston based AI biotech firm to combine AI driven Organ on a Chip platforms with computer vision image analysis. The goal is to enhance research efficiency and data reproducibility.
Antibody Development with Galux The company partnered with Galux to utilize the "GaluxDesign" platform which uses AI and physicochemical principles for de novo antibody design.
Industry analysts evaluate Woojung Bio as evolving beyond a traditional CRO into a "Next Generation Preclinical Total Solution" provider positioning it well amid tightening global regulations on animal testing.
Kukjeon Pharmaceutical stock trend on Mar 3.(Image=MP Doctor)
◇Kukjeon Pharmaceutical 14% Jump as HBM Material Production Nears
Kukjeon Pharmaceutical closed at 4,715 won up 14%. Investor sentiment was buoyed by the company’s success in localizing materials for the HBM (High Bandwidth Memory) process and plans to begin mass production this March.
The company is currently pivoting from its traditional focus on Active Pharmaceutical Ingredients (APIs) to becoming an "Advanced Electronic Materials" enterprise. Key highlights include:
Resilient Fundamentals Despite a slight dip in annual revenue (131 billion won), the company maintained stability.
Healthy Deficit While the company reported an operating loss of 2.6 billion won, the market views this as a "strategic investment phase" for new semiconductor material lines and conservative accounting regarding one time bad debt expenses.
Financial Stability: The company reduced its debt by over 30 billion won, bringing its debt-to-equity ratio down to a stable 87%.
A sharp turnaround in earnings is expected as semiconductor material production ramps up in the first quarter.
CG Medtech stock trend on Mar 3.(Image=MP Doctor)
◇CG Medtech Strong 12% Gain Fueled by Implants and Skin Boosters
CG Medtech rose 12% to close at 3,015 won. The rally follows a high intensity business reorganization after a change in majority ownership focusing on two growth pillars Dental Implants and Extracellular Matrix (ECM) Skin Boosters.
The company has successfully built a comprehensive digital dentistry value chain through the acquisition of firms like GDS and Dental Ocean.
The "Urudent" Launch In Q1, the company will launch "Urudent" a dental implant brand utilizing Daewoong Pharmaceutical's intellectual property.
Capacity Expansion A new factory will increase production capacity threefold from 200,000 to 600,000 units facilitating OEM/ODM expansion.
Skin Booster Synergy NH Investment & Securities researcher Kang Kyeong geun noted that CG Medtech will handle the ODM production of "CGRialloinject Fine" a new skin booster from its parent company CG Medtech. The combination of high quality raw materials and Daewoong’s distribution network via DN Company is expected to drive significant growth.
